Tags

Type your tag names separated by a space and hit enter

Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis.
Cardiol J 2010; 17(3):259-66CJ

Abstract

BACKGROUND

Perindopril, a long-acting angiotensin converting enzyme-inhibitor, reduces incidence of cardiovascular end points in a wide range of patients. This effect depends on both the antihypertensive and blood pressure lowering unrelated effects. The aim of the study was to check the possible influence of patients' clinical profile on the antihypertensive efficacy of perindopril.

METHODS

A meta-analysis of individual data of hypertensive patients enrolled in five open studies tested the efficacy and safety of perindopril over a 12-week treatment period.

RESULTS

We included data of 3,188 men (39%) and women, aged on average 53 years, whose baseline systolic/diastolic blood pressure averaged 163/99 mm Hg and on average declined by 27/17 mm Hg. Mean duration of hypertension was five years, and 34% of patients had prior cardiovascular complications. We found no difference in the antihypertensive effect of perindopril in patients with complicated vs non-complicated hypertension (DSBP 0.05, 95%CI: -1.5 to 1.6 mm Hg, p = 0.95), in older vs younger patients (DSBP 2.4, 95%CI: -3.2 to 7.9 mm Hg, p = 0.41), in men vs women (DSBP -1.43, 95%CI: -3.4 to 0.5, p = 0.15), and in patients with long-lasting vs shorter duration of hypertension (DSBP 0.0, 95%CI: -1.0 to 1.0 mm Hg, p = 1.0). The antihypertensive effect of perindopril was stronger in patients with greater (> or = 160 mm Hg) systolic blood pressure (DSBP 12.3, 95%CI: 5.5 to 19.0, p = 0.0004). The effect on diastolic blood pressure tended to be greater in younger patients (DDBP -0.63, 95%CI: -1.2 to -0.02 mm Hg, p = 0.04).

CONCLUSIONS

Perindopril is an effective antihypertensive medication. Seems not to be adversely affected by the clinical profile of the patient.

Authors+Show Affiliations

Department of Gerontology and Internal Medicine, Jagiellonian University, Kraków, Poland. jerzy.gasowski@wp.plNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20535716

Citation

Gasowski, Jerzy, et al. "Short-term Antihypertensive Efficacy of Perindopril According to Clinical Profile of 3,188 Patients: a Meta-analysis." Cardiology Journal, vol. 17, no. 3, 2010, pp. 259-66.
Gasowski J, Wilkins A, Drzewoski J, et al. Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis. Cardiol J. 2010;17(3):259-66.
Gasowski, J., Wilkins, A., Drzewoski, J., Kłoś, J., Gaciong, Z., Kabat, M., & Grodzicki, T. (2010). Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis. Cardiology Journal, 17(3), pp. 259-66.
Gasowski J, et al. Short-term Antihypertensive Efficacy of Perindopril According to Clinical Profile of 3,188 Patients: a Meta-analysis. Cardiol J. 2010;17(3):259-66. PubMed PMID: 20535716.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis. AU - Gasowski,Jerzy, AU - Wilkins,Arleta, AU - Drzewoski,Józef, AU - Kłoś,Jadwiga, AU - Gaciong,Zbigniew, AU - Kabat,Marek, AU - Grodzicki,Tomasz, PY - 2010/6/11/entrez PY - 2010/6/11/pubmed PY - 2010/9/21/medline SP - 259 EP - 66 JF - Cardiology journal JO - Cardiol J VL - 17 IS - 3 N2 - BACKGROUND: Perindopril, a long-acting angiotensin converting enzyme-inhibitor, reduces incidence of cardiovascular end points in a wide range of patients. This effect depends on both the antihypertensive and blood pressure lowering unrelated effects. The aim of the study was to check the possible influence of patients' clinical profile on the antihypertensive efficacy of perindopril. METHODS: A meta-analysis of individual data of hypertensive patients enrolled in five open studies tested the efficacy and safety of perindopril over a 12-week treatment period. RESULTS: We included data of 3,188 men (39%) and women, aged on average 53 years, whose baseline systolic/diastolic blood pressure averaged 163/99 mm Hg and on average declined by 27/17 mm Hg. Mean duration of hypertension was five years, and 34% of patients had prior cardiovascular complications. We found no difference in the antihypertensive effect of perindopril in patients with complicated vs non-complicated hypertension (DSBP 0.05, 95%CI: -1.5 to 1.6 mm Hg, p = 0.95), in older vs younger patients (DSBP 2.4, 95%CI: -3.2 to 7.9 mm Hg, p = 0.41), in men vs women (DSBP -1.43, 95%CI: -3.4 to 0.5, p = 0.15), and in patients with long-lasting vs shorter duration of hypertension (DSBP 0.0, 95%CI: -1.0 to 1.0 mm Hg, p = 1.0). The antihypertensive effect of perindopril was stronger in patients with greater (> or = 160 mm Hg) systolic blood pressure (DSBP 12.3, 95%CI: 5.5 to 19.0, p = 0.0004). The effect on diastolic blood pressure tended to be greater in younger patients (DDBP -0.63, 95%CI: -1.2 to -0.02 mm Hg, p = 0.04). CONCLUSIONS: Perindopril is an effective antihypertensive medication. Seems not to be adversely affected by the clinical profile of the patient. SN - 1897-5593 UR - https://www.unboundmedicine.com/medline/citation/20535716/Short_term_antihypertensive_efficacy_of_perindopril_according_to_clinical_profile_of_3188_patients:_A_meta_analysis_ L2 - http://www.cardiologyjournal.org/en/darmowy_pdf.phtml?id=96&indeks_art=1319 DB - PRIME DP - Unbound Medicine ER -